Dose Selection in Phase I Studies: Why We Should Always Go for the Top

This publication has 12 references indexed in Scilit:

• Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
  Journal of Clinical Oncology, 2008
• Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
  Journal of Clinical Oncology, 2008
• Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
  Journal of Clinical Oncology, 2008
• RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model
  Clinical Cancer Research, 2007
• The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy
  Clinical Cancer Research, 2007
• Targeting HER2 in Prostate Cancer: Where to Next?
  Journal of Clinical Oncology, 2007
• Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
  European Journal Of Cancer, 2005
• Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
  Journal of Clinical Oncology, 2004
• Antitumor Efficacy of Intermittent Treatment Schedules with the Rapamycin Derivative RAD001 Correlates with Prolonged Inactivation of Ribosomal Protein S6 Kinase 1 in Peripheral Blood Mononuclear Cells
  Cancer Research, 2004
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
  The Lancet, 2001